Structural Heart Disease w/TAVR for Aortic Stenosis

PFO Closure

Resynchronization Pacing for CHF Patients and Coronary Intervention

Watchman Atrial Appendage Exclusion for patients with atrial fibrillation unable to take anticoagulation

Angioplasty with stent placement

Cardiac catheterization


EKG (electrocardiogram)

Exercise electrocardiogram (stress test)

Pacemaker placement

Vascular screenings: Cardiovascular risk factor assessment, Carotid quick scan, Abdominal aortic aneurysm screen, Peripheral artery disease scan

Dr. Steven K. Rowe and the CoxHealth team were one of the first in the United States to implement a Transcatheter Aortic Valve Replacement (TAVR) Program.

With over 100 successful procedures completed, Dr. Rowe’s team is leading the future of non-invasive surgery.

To Learn More Contact :

Dr. Steven K. Rowe
Keys Medical Group (Cardiology)
3428 N. Roosevelt Blvd.,
Key West, FL 33040

Phone Calls:

(305) 294-5727

Transcatheter Aortic Valve Replacement (TAVR), is the replacement of the aortic valve of the heart through blood vessels (as opposed to valve replacement through open heart surgery). With TAVR, the replacement valve is delivered via catheter using one of several access methods: transfemoral (in the upper leg), transapical (through the wall of the heart), subclavian (beneath the collar bone), and direct aortic (through a minimally invasive surgical incision into the aorta).

Learn More:

For more information about TAVR devices, please see the Medtronic CoreValve device (a self-expanding valve prosthesis consisting of a Nickel-titanium frame with a tri-leaflet valve fashioned out of porcine pericardium mounted within) and the SAPIEN device by Edwards Lifesciences (a balloon-expandable tubular metal stent with a tri-leaflet valve fashioned out of bovine percardium mounted within).

The catheter procedure was developed in France, initially performed in 2002 on April 16 by Prof Alain Cribier.  It is now approved in more than 50 countries. It is effective in improving functioning in the patients with severe aortic stenosis. In the US, it received FDA approval in November 2011 for use in inoperable patients and in October 2012 for use in patients at high surgical risk.[6]

About TAVR

Transcatheter Aortic Valve Replacement (TAVR) is a procedure for select patients with severe symtomatic aortic stenosis (narrowing of the aortic valve opening) who are not candidates for traditional open chest surgery or are high-risk operable candidates.